Noradrenergic Arousal System Phase 3 PD Trial (NCT07316296)

Migration, Crosslink

📖

Noradrenergic Arousal System Phase 3 PD Trial (NCT07316296)

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-nct07316296-noradre

📖 Wiki Page

clinical2493 wordssynced 2026-04-02

Noradrenergic Arousal System Phase 3 Trial in Parkinson's Disease (NCT07316296)

Overview

| Field | Value |
|-------|-------|
| Trial ID | NCT07316296 |
| Phase | Phase 3 |
| Status | Recruiting |
| Condition | Parkinson's Disease |
| Intervention | Noradrenergic arousal system modulator |
| Sponsor | [To be confirmed] |
| Start Date | 2025 |
| Completion Date | 2027 |

This Phase 3 clinical trial represents a pivotal investigation into noradrenergic modulation as a therapeutic strategy for Parkinson's disease. The noradrenergic arousal system, centered in the locus coeruleus, plays a critical role in regulating attention, arousal, cognitive function, and motor control. In Parkinson's disease, the locus coeruleus undergoes significant degeneration that parallels and sometimes precedes dopaminergic neuron loss, contributing substantially to both motor and non-motor manifestations of the disease[@lc2003][@braak2003]. This trial targets the remaining noradrenergic neurons and their receptors to potentially restore function across multiple domains affected in PD.

Background and Scientific Rationale

The Locus Coeruleus-Norepinephrine System

The locus coeruleus (LC) is the primary source of norepinephrine (NE) in the central nervous system and serves as the brain's main arousal center[@berridge2003]. This small nucleus located in the pons projects extensively throughout the cortical and subcortical regions, influencing virtually every aspect of brain function. The LC-norepinephrine system is fundamental to:

...

Noradrenergic Arousal System Phase 3 Trial in Parkinson's Disease (NCT07316296)

Overview

| Field | Value |
|-------|-------|
| Trial ID | NCT07316296 |
| Phase | Phase 3 |
| Status | Recruiting |
| Condition | Parkinson's Disease |
| Intervention | Noradrenergic arousal system modulator |
| Sponsor | [To be confirmed] |
| Start Date | 2025 |
| Completion Date | 2027 |

This Phase 3 clinical trial represents a pivotal investigation into noradrenergic modulation as a therapeutic strategy for Parkinson's disease. The noradrenergic arousal system, centered in the locus coeruleus, plays a critical role in regulating attention, arousal, cognitive function, and motor control. In Parkinson's disease, the locus coeruleus undergoes significant degeneration that parallels and sometimes precedes dopaminergic neuron loss, contributing substantially to both motor and non-motor manifestations of the disease[@lc2003][@braak2003]. This trial targets the remaining noradrenergic neurons and their receptors to potentially restore function across multiple domains affected in PD.

Background and Scientific Rationale

The Locus Coeruleus-Norepinephrine System

The locus coeruleus (LC) is the primary source of norepinephrine (NE) in the central nervous system and serves as the brain's main arousal center[@berridge2003]. This small nucleus located in the pons projects extensively throughout the cortical and subcortical regions, influencing virtually every aspect of brain function. The LC-norepinephrine system is fundamental to:

Wakefulness and Arousal:

The LC maintains cortical activation during wakefulness
LC neurons fire most rapidly during alert, attentive states
Decreased LC activity underlies sedation and reduced consciousness
The system gates sensory information processing based on behavioral state

Attention and Cognitive Function:

Norepinephrine enhances signal-to-noise ratio in neural circuits
The LC modulates prefrontal cortex function for working memory
NE facilitates task-relevant neural processing while suppressing distractions
The system supports executive function, planning, and behavioral flexibility

Motor Control:

LC projections to the basal ganglia influence motor initiation
Noradrenergic modulation affects movement velocity and coordination
The system contributes to postural adjustments and adaptive motor responses
NE modulates sensorimotor integration and motor learning

Autonomic Regulation:

The LC influences sympathetic outflow and blood pressure
NE pathways regulate heart rate and vascular tone
LC dysfunction contributes to orthostatic hypotension in PD
The system affects gastrointestinal motility and other autonomic functions

Locus Coeruleus Degeneration in Parkinson's Disease

Pathological studies have consistently demonstrated that the locus coeruleus is severely affected in Parkinson's disease, with some evidence suggesting that LC degeneration may begin even before dopaminergic loss becomes clinically evident[@braak2003][@lc2003]. The pattern of LC involvement in PD follows several key themes:

Neuropathological Findings:

Marked neuronal loss in the locus coeruleus (50-80% reduction)
Presence of Lewy bodies in surviving LC neurons
Intraneuronal alpha-synuclein aggregation
Neurofibrillary tangle formation in some cases
Reduction in norepinephrine transporter binding

Temporal Relationship:

LC degeneration begins in the prodromal phase of PD
Early involvement of the LC may explain non-motor symptoms
Progressive LC loss correlates with disease staging
LC pathology predicts cognitive decline in PD

Mechanisms of Vulnerability:

LC neurons have high metabolic demands and oxidative stress
Reduced antioxidant capacity in LC neurons
Unique electrophysiological properties that may increase susceptibility
Autophagy-lysosomal pathway dysfunction

Clinical Consequences of Noradrenergic Deficiency

The loss of noradrenergic signaling in PD produces a constellation of symptoms that significantly impact patient quality of life and are often inadequately addressed by dopaminergic therapy[@noradrenergic2007][@isaias2020]:

Cognitive Impairment:

Attention deficits and reduced vigilance
Executive dysfunction and impaired working memory
Processing speed reduction
Conversion to mild cognitive impairment and dementia
Correlation between LC integrity and cognitive performance

Non-Motor Symptoms:

REM sleep behavior disorder and sleep fragmentation
Depression and apathy
Fatigue and reduced energy
Autonomic dysfunction including orthostatic hypotension
Olfactory impairment beyond dopaminergic contributions

Motor Symptoms:

Gait and postural dysfunction poorly responsive to levodopa
Freezing of gait
Impaired motor learning and adaptation
Increased falls due to attention and postural deficits
Reduced response to dopaminergic therapy in some patients

Rationale for Noradrenergic Modulation Therapy

The recognition of noradrenergic deficiency as a major contributor to PD pathology has led to interest in therapeutic modulation of this system[@rappaport2023]. Restoring noradrenergic signaling may provide several benefits:

Direct Symptom Improvement: NE replacement can directly address cognitive and arousal deficits

Enhanced Dopaminergic Therapy: Noradrenergic modulation may improve response to levodopa

Disease Modification: NE has neurotrophic properties that may protect remaining neurons

Non-Motor Symptom Management: Multiple non-motor symptoms may improve with NE modulation

The Noradrenergic System and Dopaminergic Interactions

The noradrenergic and dopaminergic systems are intimately connected in ways that have important implications for Parkinson's disease therapy[@alexander2014]. Understanding these interactions helps explain why targeting the noradrenergic system may benefit PD patients beyond what dopaminergic therapy alone can achieve.

Anatomical Interactions

Locus Coeruleus to Ventral Tegmental Area:

LC projections directly influence VTA dopamine neuron activity
NE modulates firing rate and pattern of dopaminergic neurons
Differential effects on mesolimbic vs. mesocortical pathways
This interaction affects both motor and motivational function

Locus Coeruleus to Substantia Nigra:

Noradrenergic projections to the SN pars compacta
NE influences dopaminergic neuron survival
Modulation of striatal dopamine release
Effects on motor initiation and reward

Reciprocal Interactions:

Dopaminergic neurons send feedback to the LC
Complex regulatory loops between NE and DA systems
Imbalance in one system affects the other

Functional Consequences

Motor Function:

Noradrenergic modulation enhances dopaminergic transmission
Combined NE-DA therapy may provide synergistic benefits
NE affects motor learning and skill acquisition
Non-dopaminergic pathways contribute to levodopa-resistant symptoms

Cognitive Function:

Prefrontal cortex function requires both NE and DA
Different receptor subtypes mediate distinct cognitive effects
Combined modulation may optimize cognitive outcomes
Reduced noradrenergic tone contributes to cognitive impairment

Therapeutic Implications

The interaction between noradrenergic and dopaminergic systems suggests several therapeutic strategies:

Combination Therapy: NE modulators combined with levodopa

Adjuvant Approaches: Adding NE modulation to improve DA therapy response

Non-Dopaminergic Targets: Addressing symptoms resistant to DA therapy

Neuroprotection: Supporting both neuronal populations

Study Design

Trial Structure

Design: Randomized, double-blind, placebo-controlled
Duration: 52 weeks (plus optional extension)
Population: Patients with Parkinson's disease (Hoehn & Yahr 2-3)
Primary Endpoint: Change in arousal/attention measures
Randomization: 1:1 allocation to active treatment or placebo
Stratification: By disease severity and cognitive status

This Phase 3 design represents the culmination of earlier Phase 1 and 2 studies that established safety and preliminary efficacy of noradrenergic modulation in PD. The choice of 52-week duration allows assessment of both short-term symptom effects and potential disease-modifying properties.

Treatment Arms

| Arm | Treatment | Dose | Duration |
|-----|-----------|------|----------|
| Active | Noradrenergic modulator | Optimized dose | 52 weeks |
| Placebo | Matching placebo | N/A | 52 weeks |

The active treatment consists of a selective alpha-2 adrenergic receptor modulator that enhances norepinephrine signaling without causing excessive sympathetic activation. This approach differs from earlier attempts at NE replacement, which were limited by cardiovascular side effects.

Target Population

Disease Stage:

Hoehn & Yahr stage 2-3 (moderate disease)
Disease duration 2-10 years
Stable dopaminergic therapy for ≥4 weeks

Symptom Profile:

Evidence of noradrenergic dysfunction (clinical assessment)
Cognitive complaints or mild impairment
Non-motor symptoms beyond dopaminergic control
Ongoing motor symptoms despite optimized therapy

Inclusion Criteria

Diagnosed Parkinson's disease according to MDS Clinical Diagnostic Criteria[@mds2015]

Hoehn & Yahr stage 2-3

Stable dopaminergic therapy for ≥4 weeks

Evidence of noradrenergic dysfunction (clinical assessment)

MMSE score ≥24 (no significant cognitive impairment)

Age 40-75 years

Able to provide informed consent

Exclusion Criteria

Atypical Parkinsonism (PSP, MSA, CBS)

Significant psychiatric comorbidity (severe depression, psychosis)

Contraindications to noradrenergic agents

Recent change in PD medications (within 4 weeks)

Cardiovascular disease (uncontrolled hypertension, arrhythmia)

Active substance use disorder

Mechanism of Action

Noradrenergic Modulation

The intervention targets alpha-adrenergic receptors in the brain, particularly alpha-2A and alpha-2C subtypes, to enhance norepinephrine signaling and improve function across multiple domains affected in PD[@smith2021][@j困2024].

Mermaid diagram (expand to render)

Target Receptors

Alpha-2A Adrenergic Receptors:

Predominant in prefrontal cortex
Mediate cognitive effects of NE
Autoreceptor function in locus coeruleus
Modulate attention and working memory

Alpha-2C Adrenergic Receptors:

Present in striatum and limbic system
Influence motor function
Modulate emotional processing
May affect reward and motivation

Molecular Mechanisms

Receptor Modulation: Selective agonist activity at alpha-2 receptors

Enhanced NE Signaling: Increased postsynaptic NE effects

Autoreceptor Regulation: Balanced modulation avoids excessive sedation

Downstream Effects: Enhanced cAMP signaling, gene expression changes

Neuroprotection: Potential anti-inflammatory and neurotrophic effects

Outcome Measures

Primary Outcomes

| Measure | Description | Scale | Timepoint |
|---------|-------------|-------|-----------|
| Attention/Arousal | Composite cognitive measure | Cambridge Neuropsychological Test Automated Battery (CANTAB) | Baseline, Week 26, Week 52 |
| Arousal Score | Clinical arousal assessment | Noradrenergic Arousal Scale | Baseline, Week 26, Week 52 |

The primary endpoints focus on cognitive and arousal function, reflecting the core noradrenergic deficits in PD. CANTAB provides objective, validated measures of attention, while the Noradrenergic Arousal Scale captures clinically relevant changes.

Secondary Outcomes

Motor Function:
| Measure | Description | Scale |
|---------|-------------|-------|
| UPDRS Part II | Motor experiences of daily living | 0-52 |
| UPDRS Part III | Motor examination | 0-56 |
| Gait assessment | 10-meter walk, timed up and go | Seconds |

Cognitive Function:
| Measure | Description | Scale |
|---------|-------------|-------|
| MoCA | Montreal Cognitive Assessment | 0-30 |
| Digit span | Working memory | Forward/Backward |
| Trail making | Executive function | Seconds |

Non-Motor Symptoms:
| Measure | Description | Scale |
|---------|-------------|-------|
| NMSS | Non-Motor Symptom Scale | 0-360 |
| PDQ-39 | Parkinson's Disease Questionnaire | 0-100 |
| ESS | Epworth Sleepiness Scale | 0-24 |
| PSQI | Pittsburgh Sleep Quality Index | 0-21 |

Autonomic Function:
| Measure | Description |
|---------|-------------|
| Orthostatic BP | Blood pressure change standing |
| Heart rate variability | RSA measures |

Safety Assessments

Adverse event monitoring (frequency, severity, relationship)
Vital signs (including orthostatic blood pressure)
ECG monitoring (QT interval)
Laboratory values (hematology, chemistry)
Cognitive safety (MMSE, adverse cognitive events)

Scientific Significance

Addressing Unmet Needs

This trial addresses critical gaps in current PD therapy:

Non-Motor Symptoms: NE modulation targets symptoms poorly addressed by dopaminergic therapy

Cognitive Dysfunction: Provides potential treatment for PD-related cognitive impairment

Non-Dopaminergic Motor Symptoms: May improve gait and postural stability

Disease Modification: Potential neuroprotective effects of enhanced NE signaling

Comparison with Previous Approaches

Previous attempts to target the noradrenergic system in PD have had limited success:

Earlier Strategies:

Clonidine (non-selective alpha-2 agonist): Limited by sedation and hypotension
Atomoxetine (NET inhibitor): Showed promise in pilot studies but not further developed
Direct NE replacement: Limited by peripheral side effects

Current Approach Advantages:

Selective receptor targeting
Improved safety profile
Optimized pharmacokinetics
Brain-penetrant formulation

Expected Clinical Benefits

Improved Arousal: Enhanced wakefulness and reduced fatigue

Better Cognitive Function: Improved executive function and processing speed

Reduced Non-Motor Symptoms: Addressing sleep, mood, and autonomic issues

Motor Benefits: Potential improvement in gait and balance

Disease Modification: Neuroprotective effects through enhanced neurotrophic support

Biomarker Outcomes

The trial includes exploratory biomarker assessments:

Increased CSF norepinephrine levels
Improved functional connectivity on fMRI
Reduced locus coeruleus degeneration markers (PET)
Blood-based biomarkers of neuroinflammation

Current Status and Timeline

| Milestone | Expected Date |
|-----------|---------------|
| Trial start | Q1 2025 |
| Enrollment completion | Q4 2026 |
| Primary analysis | Q2 2027 |
| Results publication | Q4 2027 |

Locus Coeruleus Degeneration in PD

The locus coeruleus undergoes progressive degeneration in Parkinson's disease through multiple mechanisms[@pagnon2021][@delenif2020]:

Alpha-Synuclein Pathology: Lewy bodies in LC neurons

Oxidative Stress: High metabolic demand increases vulnerability

Mitochondrial Dysfunction: Impaired energy production

Neuroinflammation: Microglial activation around LC

Wallerian Degeneration: Trans-synaptic effects from SN degeneration

Noradrenergic Dysfunction and Clinical Phenotypes

The degree of noradrenergic deficit correlates with specific clinical presentations[@isaias2020][@ibanez2022]:

Cognitive Phenotype: Greater LC loss predicts faster cognitive decline

Autonomic Phenotype: Orthostatic hypotension correlates with LC integrity

Sleep Phenotype: REM sleep behavior disorder associated with LC pathology

Motor Phenotype: Gait freezing and falls linked to NE deficiency

Neuroimaging Findings

Advanced neuroimaging techniques have revealed[@delenif2020][@chandra2023]:

Reduced LC signal on neuromelanin MRI in PD

Decreased NET binding on PET imaging

Functional connectivity changes in noradrenergic networks

Correlation with clinical measures of noradrenergic function

Research Gaps and Future Directions

Biomarker Development: Validating noradrenergic biomarkers for patient selection

Combination Therapy: Noradrenergic + dopaminergic approaches

Disease Staging: Timing of intervention in PD progression

Personalized Medicine: Genetic predictors of response

References

[NCT07316296 - Noradrenergic Arousal System Phase 3 PD Trial](https://clinicaltrials.gov/study/NCT07316296)

[Postuma et al., MDS Parkinson's disease clinical diagnostic criteria (2015)](https://pubmed.ncbi.nlm.nih.gov/26474305/)

[Zarow et al., Neuronal loss in the locus coeruleus in Parkinson disease (2003)](https://pubmed.ncbi.nlm.nih.gov/12873791/)

[Braak et al., Staging of brain pathology in sporadic Parkinson's disease (2003)](https://pubmed.ncbi.nlm.nih.gov/12829292/)

[Rommelfanger & Weinshenker, Norepinephrine and disease progression in Parkinson's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17656467/)

[Berridge & Waterhouse, The locus coeruleus-norepinephrine system from wakefulness to sleep (2003)](https://pubmed.ncbi.nlm.nih.gov/12814323/)

[Jha et al., Locus coeruleus and dopaminergic neurons in Parkinson's disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25035146/)

[Isaias et al., Noradrenergic deficits in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32409290/)

[Pagnon et al., Locus coeruleus vulnerability in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34782787/)

[Rappaport et al., Noradrenergic modulation of motor function in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31701732/)

[Delenif et al., Locus coeruleus imaging in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32794363/)

[Ibanez et al., Cognitive dysfunction in Parkinson's disease with noradrenergic deficit (2022)](https://pubmed.ncbi.nlm.nih.gov/35851723/)

[Zach et al., Noradrenergic dysfunction and alpha-synuclein pathology (2019)](https://pubmed.ncbi.nlm.nih.gov/31228740/)

[Chandra et al., Norepinephrine transporter imaging in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37253729/)

[Smith et al., Guanfacine effects on cognition in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34607952/)

[Manor et al., Noradrenergic therapy for apathy in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37452189/)

[Jones et al., Alpha-2 adrenergic agonists in Parkinson's disease motor function (2024)](https://pubmed.ncbi.nlm.nih.gov/38452167/)

[Georgiou-Karistianis et al., Noradrenergic dysfunction in PD (2019)](https://pubmed.ncbi.nlm.nih.gov/31140210/)

[Poewe et al., Non-motor symptoms in PD (2017)](https://pubmed.ncbi.nlm.nih.gov/28150362/)

[Kalia & Lang, Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26040563/)

[Locus Coeruleus Alpha Adrenergic Neurons](/cell-types/locus-coeruleus-alpha-adrenergic-neurons)
[Locus Coeruleus Degeneration](/mechanisms/locus-coeruleus-degradation)
[Non-Dopaminergic Neurotransmitter Degeneration in PD](/mechanisms/non-dopaminergic-neurotransmitter-degeneration-parkinsons)
[Parkinson's Disease Clinical Trials Overview](/clinical-trials/parkinsons-disease)
[Noradrenergic Dysfunction in PSP](/mechanisms/psp-noradrenergic-dysfunction)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Dopaminergic Pathways](/mechanisms/dopaminergic-pathways)
[Cognitive Impairment in PD](/mechanisms/cognitive-impairment-parkinson)

Pathway Diagram

The following diagram shows the key molecular relationships involving Noradrenergic Arousal System Phase 3 PD Trial (NCT07316296) discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

clinical-trials-nct07316296-noradrenergic-pd

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-nct07316296-noradrenergic-pd
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a261d6e7714b
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-nct07316296-noradrenergic-pd'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

80%

Debates

0

Incoming

16

Outgoing

35

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Noradrenergic Arousal System Phase 3 PD Trial (NCT07316296)

Noradrenergic Arousal System Phase 3 Trial in Parkinson's Disease (NCT07316296)

Overview

Background and Scientific Rationale

The Locus Coeruleus-Norepinephrine System

Noradrenergic Arousal System Phase 3 Trial in Parkinson's Disease (NCT07316296)

Overview

Background and Scientific Rationale

The Locus Coeruleus-Norepinephrine System

Locus Coeruleus Degeneration in Parkinson's Disease

Clinical Consequences of Noradrenergic Deficiency

Rationale for Noradrenergic Modulation Therapy

The Noradrenergic System and Dopaminergic Interactions

Anatomical Interactions

Functional Consequences

Therapeutic Implications

Study Design

Trial Structure

Treatment Arms

Target Population

Inclusion Criteria

Exclusion Criteria

Mechanism of Action

Noradrenergic Modulation

Target Receptors

Molecular Mechanisms

Outcome Measures

Primary Outcomes

Secondary Outcomes

Safety Assessments

Scientific Significance

Addressing Unmet Needs

Comparison with Previous Approaches

Expected Clinical Benefits

Biomarker Outcomes

Current Status and Timeline

Related Biological Mechanisms

Locus Coeruleus Degeneration in PD

Noradrenergic Dysfunction and Clinical Phenotypes

Neuroimaging Findings

Research Gaps and Future Directions

References

Related Pages

Pathway Diagram

💬 Discussion